Patents by Inventor Minutza Leibovici

Minutza Leibovici has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-N-{5-[ [4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
    Publication number: 20100081695
    Abstract: Disclosed is an isolated compound of the formula: along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate.
    Type: Application
    Filed: November 24, 2009
    Publication date: April 1, 2010
    Inventors: Yehudit Dolitzky, Yoseph Avezov, Dina Spivak, Minutza Leibovici, Ben-Zion Solomon
  • 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
    Patent number: 7632841
    Abstract: Disclosed is an isolated compound of the formula: along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: December 15, 2009
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Yehudit Dolitzky, Yoseph Avezov, Dina Spivak, Minutza Leibovici, Ben-Zion Solomon
  • Formulations of candesartan
    Publication number: 20090048317
    Abstract: The present invention encompasses pharmaceutical compositions comprising candesartan and processes for preparing the same. In particular, a pharmaceutical composition comprising candesartan or a prodrug thereof or an analog thereof or a derivative thereof and at least one non-ionic surfactant, wherein the pharmaceutical composition has about 0.01% to about 10% of at least one non-ionic surfactant present in the total weight of the composition.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 19, 2009
    Inventors: Michael Fox, Minutza Leibovici, Itamar Kanari
  • Pharmaceutical composition comprising candesartan cilexetil
    Publication number: 20090048316
    Abstract: The present invention encompasses pharmaceutical compositions comprising candesartan cilexetil, an amino acid and a pharmaceutically acceptable excipient, and processes for preparing the same.
    Type: Application
    Filed: March 10, 2008
    Publication date: February 19, 2009
    Inventors: Minutza Leibovici, Itamar Kanari, Michael Fox
  • Pharmaceutical excipient complex
    Publication number: 20090018175
    Abstract: The present invention encompasses pharmaceutical excipient complexes comprising combining at least one carrier with an oily substance, and processes for preparing the same, stable pharmaceutical compositions comprising such complexes and active pharmaceutical ingredients and processes for preparing the same.
    Type: Application
    Filed: April 25, 2008
    Publication date: January 15, 2009
    Inventors: Itamar Kanari, Michael Fox, Minutza Leibovici
  • 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
    Patent number: 7435741
    Abstract: Disclosed is an isolated compound of the formula: along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: October 14, 2008
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Yehudit Dolitzky, Yoseph Avezov, Dina Spivak, Minutza Leibovici, Ben-Zion Solomon
  • Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
    Patent number: 7396542
    Abstract: Provided are formulations of a stable commercial paroxetine tablet comprising paroxetine hydrochloride anhydrous, povidone, copovidone or HPMC as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: July 8, 2008
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Michael Fox, Rakefet Cohen, Anne Braunstein, Minutza Leibovici
  • 2-N butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
    Publication number: 20070265313
    Abstract: Disclosed is an isolated compound of the formula: along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate.
    Type: Application
    Filed: October 20, 2006
    Publication date: November 15, 2007
    Inventors: Yehudit Dolitzky, Yoseph Avezov, Dina Spivak, Minutza Leibovici, Ben-Zion Solomon
  • 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
    Publication number: 20070265312
    Abstract: Disclosed is an isolated compound of the formula: along with methods of detecting it and of minimizing it in improved pharmaceutical compositions of rosiglitazone maleate.
    Type: Application
    Filed: May 9, 2006
    Publication date: November 15, 2007
    Inventors: Yehudit Dolitzky, Yoseph Avezov, Dina Spivak, Minutza Leibovici, Ben-Zion Solomon
  • Dipyridamole extended-release formulations and process for preparing same
    Publication number: 20070184110
    Abstract: The invention is directed to a dipyridamole formulation comprising an extended release formulation of dipyridamole and a pharmaceutically acceptable carboxylic acid, wherein the formulation is in a tablet solid form having a diameter of about 1.5 mm to about 3 mm. Optionally, the formulation may further comprise an immediate release acetylsalicylic acid formulation.
    Type: Application
    Filed: February 13, 2006
    Publication date: August 9, 2007
    Inventors: Minutza Leibovici, Itamar Kanari, Michael Fox
  • Methods of formulating linezolid
    Publication number: 20070020329
    Abstract: A method of formulating linezolid to provide a pharmaceutical composition comprising linezolid wherein the linezolid is linezolid Form IV substantially free of linezolid Form II, a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II and povidone, methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV substantially free of linezolid Form II, and methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV and povidone.
    Type: Application
    Filed: January 17, 2006
    Publication date: January 25, 2007
    Inventors: Ruth Tenengauzer, Minutza Leibovici, Ben-Zion Solomon
  • Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
    Publication number: 20050191350
    Abstract: Provided are formulations of a stable commercial paroxetine tablet comprising paroxetine hydrochloride anhydrous, povidone, copovidone or HPMC as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method.
    Type: Application
    Filed: April 14, 2005
    Publication date: September 1, 2005
    Inventors: Michael Fox, Rakefet Cohen, Anne Braunstein, Minutza Leibovici
  • Stable pergolide mesylate and process for making same
    Patent number: 6689384
    Abstract: A formulation and a method for manufacturing pergolide mesylate is disclosed whereby substantially stable pergolide mesylate can be manufactured without having to introduce stabilizing additives.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: February 10, 2004
    Assignee: Teva Pharmaceuticals Industries Ltd.
    Inventors: Ruth Tenengauzer, Minutza Leibovici
  • Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
    Publication number: 20030144324
    Abstract: Provided are formulations of a stable commercial paroxetine tablet comprising paroxetine hydrochloride anhydrous, povidone, copovidone or HPMC as a binder, and an HCl free/non-hygroscopic filler, prepared by the wet granulation method.
    Type: Application
    Filed: December 27, 2002
    Publication date: July 31, 2003
    Inventors: Michael Fox, Rakefet Cohen, Anne Braunstein, Minutza Leibovici
  • Stable pharmaceutical formulation comprising torsemide modification II
    Publication number: 20030022921
    Abstract: Novel, stable pharmaceutical formulations for the oral administration of high purity torsemide modification II are disclosed. These formulations release high purity torsemide modification II in water at a constant and high purity rate, and the high purity torsemide modification II therein does not rearrange to torsemide modification I over time. Methods for their manufacture are also disclosed.
    Type: Application
    Filed: February 8, 2002
    Publication date: January 30, 2003
    Inventors: Minutza Leibovici, Ruth Tenengauzer, Mira Kopel, Judith Aronhime, Marco Kordova
  • Stable pharmaceutical formulation comprising torsemide modification II
    Patent number: 6482417
    Abstract: Novel, stable pharmaceutical formulations for the oral administration of high purity torsemide modification II are disclosed. These formulations release high purity torsemide modification II in water at a constant and high purity rate, and the high purity torsemide modification II therein does not rearrange to torsemide modification I over time. Methods for their manufacture are also disclosed.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: November 19, 2002
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Minutza Leibovici, Ruth Tenengauzer, Mira Kopel, Judith Aronhime, Marco Kordova
  • Stable pergolide mesylate and process for making same
    Publication number: 20020054904
    Abstract: A formulation and a method for manufacturing pergolide mesylate is disclosed whereby substantially stable pergolide mesylate can be manufactured without having to introduce stabilizing additives.
    Type: Application
    Filed: August 7, 2001
    Publication date: May 9, 2002
    Inventors: Ruth Tenengauzer, Minutza Leibovici
  • Stable pharmaceutical formulation comprising torsemide modification II
    Publication number: 20020035135
    Abstract: Novel, stable pharmaceutical formulations for the oral administration of high purity torsemide modification II are disclosed. These formulations release high purity torsemide modification II in water at a constant and high purity rate, and the high purity torsemide modification II therein does not rearrange to torsemide modification I over time. Methods for their manufacture are also disclosed.
    Type: Application
    Filed: February 21, 2001
    Publication date: March 21, 2002
    Inventors: Minutza Leibovici, Ruth Tenengauzer, Mira Kopel, Judith Aronhime, Marco Kordova